The combinations of cytokine and ACT are currently being evaluated in multiple clinical trials in a variety of cancer types, including with different doses of IL-2 (NCT02414945, NCT04052334) or using IL-15 and IL-2 as an adjuvant for NK cell infusion (NCT03669172, NCT03213964). The gene discussed is IL15; the disease is cancer.